WO2011129428A1 - Composition cosmétique contenant de l'extrait de prunier - Google Patents
Composition cosmétique contenant de l'extrait de prunier Download PDFInfo
- Publication number
- WO2011129428A1 WO2011129428A1 PCT/JP2011/059358 JP2011059358W WO2011129428A1 WO 2011129428 A1 WO2011129428 A1 WO 2011129428A1 JP 2011059358 W JP2011059358 W JP 2011059358W WO 2011129428 A1 WO2011129428 A1 WO 2011129428A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ume
- extract
- present
- skin
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 108
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 239000002537 cosmetic Substances 0.000 title claims description 30
- 244000018795 Prunus mume Species 0.000 claims abstract description 129
- 230000000694 effects Effects 0.000 claims abstract description 98
- 230000005764 inhibitory process Effects 0.000 claims abstract description 31
- 108010003272 Hyaluronate lyase Proteins 0.000 claims abstract description 19
- 102000001974 Hyaluronidases Human genes 0.000 claims abstract description 19
- 229960002773 hyaluronidase Drugs 0.000 claims abstract description 19
- 102000016387 Pancreatic elastase Human genes 0.000 claims abstract description 15
- 108010067372 Pancreatic elastase Proteins 0.000 claims abstract description 15
- 230000002087 whitening effect Effects 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 61
- 230000002401 inhibitory effect Effects 0.000 claims description 45
- 239000008213 purified water Substances 0.000 claims description 40
- 239000003995 emulsifying agent Substances 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 23
- -1 steam Substances 0.000 claims description 23
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 17
- 239000000469 ethanolic extract Substances 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 17
- 230000008099 melanin synthesis Effects 0.000 claims description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 14
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 10
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims description 7
- 229930182558 Sterol Natural products 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 6
- 235000019438 castor oil Nutrition 0.000 claims description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 6
- 150000003432 sterols Chemical class 0.000 claims description 6
- 235000003702 sterols Nutrition 0.000 claims description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 5
- 244000068988 Glycine max Species 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 235000011158 Prunus mume Nutrition 0.000 abstract description 124
- 230000003712 anti-aging effect Effects 0.000 abstract description 3
- 239000003125 aqueous solvent Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 51
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 24
- 239000007788 liquid Substances 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 17
- 239000006210 lotion Substances 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
- 108060005980 Collagenase Proteins 0.000 description 13
- 102000029816 Collagenase Human genes 0.000 description 13
- 229960002424 collagenase Drugs 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 239000012071 phase Substances 0.000 description 13
- 108010026132 Gelatinases Proteins 0.000 description 11
- 102000013382 Gelatinases Human genes 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000006071 cream Substances 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- 235000013399 edible fruits Nutrition 0.000 description 10
- 230000008030 elimination Effects 0.000 description 10
- 238000003379 elimination reaction Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 239000003921 oil Substances 0.000 description 8
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000000787 lecithin Substances 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 229940067606 lecithin Drugs 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000021018 plums Nutrition 0.000 description 5
- 239000000344 soap Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000001256 steam distillation Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 238000003691 Amadori rearrangement reaction Methods 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 108010003541 Platelet Activating Factor Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000004332 deodorization Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 208000018191 liver inflammation Diseases 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 2
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- GKHCBYYBLTXYEV-HENWMNBSSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-phenylmethoxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCC1=CC=CC=C1 GKHCBYYBLTXYEV-HENWMNBSSA-N 0.000 description 1
- VADSVXSGIFBZLI-IBEHDNSVSA-N (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-(2-methoxy-4-prop-2-enylphenoxy)oxane-3,4,5-triol Chemical compound COC1=CC(CC=C)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VADSVXSGIFBZLI-IBEHDNSVSA-N 0.000 description 1
- RRUYWEMUWIRRNB-LURJTMIESA-N (2s)-6-amino-2-[carboxy(methyl)amino]hexanoic acid Chemical compound OC(=O)N(C)[C@H](C(O)=O)CCCCN RRUYWEMUWIRRNB-LURJTMIESA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- VKGQPUZNCZPZKI-UHFFFAOYSA-N (diaminomethylideneamino)azanium;sulfate Chemical compound NN=C(N)N.NN=C(N)N.OS(O)(=O)=O VKGQPUZNCZPZKI-UHFFFAOYSA-N 0.000 description 1
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical compound O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical group [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- GVUGADOWXGKRAE-SRVKXCTJSA-N 4-[[(2s)-1-[[(2s)-1-[[(2s)-1-(4-nitroanilino)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 GVUGADOWXGKRAE-SRVKXCTJSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- GKHCBYYBLTXYEV-UHFFFAOYSA-N Benzyl glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC1=CC=CC=C1 GKHCBYYBLTXYEV-UHFFFAOYSA-N 0.000 description 1
- 244000274847 Betula papyrifera Species 0.000 description 1
- 235000009113 Betula papyrifera Nutrition 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 235000010928 Betula populifolia Nutrition 0.000 description 1
- 235000002992 Betula pubescens Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002160 Celluloid Polymers 0.000 description 1
- 241000723438 Cercidiphyllum japonicum Species 0.000 description 1
- 240000001825 Chimonanthus praecox Species 0.000 description 1
- 235000007519 Chimonanthus praecox Nutrition 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000193159 Hathewaya histolytica Species 0.000 description 1
- 241000251511 Holothuroidea Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000219995 Wisteria Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- SUXVWSIPTXXPOZ-UHFFFAOYSA-N demethyleugenol beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(CC=C)C=C1O SUXVWSIPTXXPOZ-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LIEMWVYKRWIQMX-UHFFFAOYSA-N eugenyl beta-D-glucopyranoside Natural products COC1=CC=C(CC=C)C=C1OC1C(O)C(O)C(O)C(CO)O1 LIEMWVYKRWIQMX-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 238000007804 gelatin zymography Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000003866 melanoblast Anatomy 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 210000003574 melanophore Anatomy 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- AYEKKSTZQYEZPU-RYUDHWBXSA-N pentosidine Chemical compound OC(=O)[C@@H](N)CCCCN1C=CC=C2N=C(NCCC[C@H](N)C(O)=O)N=C12 AYEKKSTZQYEZPU-RYUDHWBXSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 108010088090 pro-matrix metalloproteinase 9 Proteins 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- WUUHFRRPHJEEKV-UHFFFAOYSA-N tripotassium borate Chemical compound [K+].[K+].[K+].[O-]B([O-])[O-] WUUHFRRPHJEEKV-UHFFFAOYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a composition containing extracts from various parts of ume.
- the composition of the present invention is particularly useful as a cosmetic or a food or drink.
- Patent Document 1 provides a cosmetic characterized by blending a ume seed extract.
- radical scavenging action collagenase activity inhibitory action (collageno kit CLN-100) was obtained from an extract obtained from ground pulverized seeds of ume (variety unknown) using water, ethanol, 1,3-butylene glycol, or methanol as a solvent.
- Use It seems to be using fluorescently labeled type I collagen.
- Hyaluronidase activity inhibitory action (details are unknown, such as origin of hyaluronidase used in the measurement), changes in cell hue in B16 cells confirmed Has been.
- lotions, shampoos, creams, body gels, hair packs, and granular bath preparations containing ume seed extract have been prepared, and sensory tests have confirmed the feeling of use.
- Patent Documents 2 to 4 include at least one selected from the group consisting of plum tree trunks, plum tree branches, plum tree leaves, plum tree stems, plum tree roots, plum meat, ume seed shells and ume seeds.
- methanol extract of Minamitakaume Jin and / or leaf stem part has an effect on gastric mucosal damage by methanol in rats, a radical (DPPH) elimination effect, an inhibitory effect on blood sugar level increase after glucose load in healthy rats, Inhibition of aldose reductase, promotion of aggregation when platelets of healthy rabbits were washed with platelet-activating factor (PAF), suppression of D-galactosamine / LPS-induced liver inflammation in healthy mice, D-in rat primary cultured hepatocytes Inhibition of galactosamine-induced acute hepatitis and inhibition of NO acid from macrophages in the abdominal cavity of healthy mice by stimulation with LPS, tyrosinase inhibitory action, radical (DPPH) elimination action, and washing of healthy rabbits of ume flower methanol extract Aggregation-promoting action has been confirmed when platelets are stimulated with platelet-activating factor (PAF)
- PAF platelet-activating factor
- Patent Document 5 describes a collagen production promoter characterized by containing an extract from the fruit part of ume as an active ingredient.
- human fibroblasts are extracted from a dried fruit juice obtained by washing, crushing, and enucleating the ume (variety unknown) fruit juice and using a mixed solvent of ethanol and water. Has been confirmed to promote collagen production (using anti-human collagen type I rabbit IgG).
- JP 2002-284633 A JP 2000-239297 A JP 2002-370922 A JP 2004-115542 A JP 2006-176425 A
- the present inventors have focused on a material called ume having a high pharmacological effect, and have developed a cosmetic characterized by comprising a fermented ume juice (No. 2526362).
- a fermented ume juice No. 2526362
- the present inventors have completed the present invention by discovering previously unknown actions such as elastase activity inhibitory action, gelatinase activity inhibitory action, Maillard reaction inhibitory action and the like.
- the present invention provides the following: [1] A group consisting of water, water vapor, purified water, mineral water, ethanol, propylene glycol, and 1,3-butylene glycol from one or more sites selected from roots, branches and bark of ume A cosmetic composition containing, as a dry powder, 0.05 to 250 mg / 100 g of an extract from one or more solvents selected from the group consisting of 0.015 to 5 g / 100 g of an emulsifier. [2] The composition according to [1], wherein the emulsifier is lysolecithin, PEG-60 hydrogenated castor oil, hydrogenated lecithin, soybean sterol, or any combination thereof.
- FIG. 1 is a photograph showing the results of a gelatinase activity inhibitory effect test.
- FIG. 2 is a photograph showing the results of the Maillard reaction inhibitory effect test.
- FIG. 3 is a photograph showing the results of a test for examining the amount of emulsifier.
- FIG. 4 is a photograph showing the results of a test for examining the amount of emulsifier.
- ume refers to ume (plum, scientific name: Prunus mume), which is a deciduous tree of the genus Rosaceae. Ume can be roughly divided into flower plums and real plums.
- Examples of real plums are Bungo, Shirakaga, Bakujuku, Moon World, Koshu Minato, Tammei, Kojo, and Minami High School.
- the term “Bungo” for ume varieties refers to Bungo classified as real plum, unless otherwise specified.
- ume refers to a plant body of a ume plant or a part thereof unless otherwise specified.
- Parts include fruits, seeds, organs or parts thereof (including leaves, roots, stems, flowers, stamens, pistils, fragments thereof), plant culture cells, callus, protoplasts, transformed plant cells, traits Converted plants are included.
- “Wakae” refers to a branch in which a new tree that grows in early spring begins to grow and grows about 5 to 30 cm, and the skin is soft, unless otherwise specified.
- the term “root” includes fine roots, medium roots and thick roots, as well as old roots and others. Fine roots are those with a diameter of less than 3 mm.
- the middle root means one having a diameter of 3 mm or more and less than 10 mm.
- a radish is one having a diameter of 10 mm or more.
- Old root is a general term for roots obtained from ume plants over 30 years old.
- any part of ume can be used effectively, but from the viewpoint that various effects can be expected, roots and branches (especially young branches) are preferable, and roots are more preferable.
- elastase refers to a protease having elastin as a typical substrate, unless otherwise specified.
- Elastin is a kind of a hard protein that is rich in elasticity and constitutes connective tissues, tendons, aortic skin, cervical cord and the like of higher animals. There are many crosslinks between peptide chains constituting this protein, which brings about elasticity.
- the term “gelatinase” is a protease using a type IV collagen that is a basement membrane component as a typical substrate, unless otherwise specified, and is a matrix metalloproteinase (MMP) group of MMP-2 and MMP-9. Is included.
- MMP matrix metalloproteinase
- the presence or absence and / or degree of the ability to inhibit the target gelatinase activity can be confirmed and measured appropriately by those skilled in the art using known means. For example, it can be carried out using a commercially available MMP marker for gelatin zymography, which contains MMP-2, ProMMP-2, ProMMP-9 or a mixture thereof.
- MMP-2 MMP-2, ProMMP-2, ProMMP-9 or a mixture thereof.
- MMP-9 for gelatin zymography
- Collagenase refers to a type of protease using type I collagen as a typical substrate, unless otherwise specified.
- Collagenase includes MMP-1, which is a matrix metalloproteinase (MMP) that degrades type I and type III collagen, which are the main components of the skin matrix.
- MMP-1 matrix metalloproteinase
- Collagen is a main component of the extracellular matrix of animals, and is known to have a physical function of maintaining the structure and exhibit cell adhesion activity. It is also contained in large amounts in the skin and is related to elasticity and strength. There are I to VIII in collagen.
- the presence or absence and / or degree of the ability to inhibit the target collagenase activity can be confirmed and measured appropriately by those skilled in the art using known means. For detailed conditions, reference can be made to the Examples section of this specification. In the present invention, the presence or absence and / or degree of inhibition of collagenase activity is based on the method described in the examples of the present specification, unless otherwise specified.
- hyaluronidase refers to an enzyme that lowers the molecular weight of hyaluronic acid, unless otherwise specified, and an enzyme that hydrolyzes the N-acetyl-D-hexosaminide bond of hyaluronic acid.
- Hyaluronidase is present in the skin.
- Hyaluronic acid is a kind of glycosaminoglycan having a repeating structure of only disaccharides of O- ⁇ -D-glucuronosyl (1 ⁇ 3) -N-acetyl- ⁇ -D-glucosaminyl (1 ⁇ 4) units. It is present in connective tissues such as animal joint fluid and dermis.
- fibroblast activation means that the proliferation ability of normal human dermal fibroblasts (NHDF) can be enhanced.
- the presence / absence / degree of cell proliferation can be determined by counting the number of living cells. Various methods are known for determining the number of viable cells.
- the presence and / or degree of the ability to activate the target fibroblasts can be confirmed and measured appropriately by those skilled in the art using known means. For detailed conditions, reference can be made to the Examples section of this specification. In the present invention, the presence or absence and / or degree of fibroblast activation activity is based on the method described in the examples of the present specification, unless otherwise specified.
- melanin production inhibition refers to inhibition of melanocyte activator synthesis, inhibition of melanocyte activator, tyrosinase synthesis / maturation inhibition, melanin synthase (tyrosinase etc.) activity inhibition, melanin, unless otherwise specified
- melanin is an oxidation polymer derived from tyrosine.
- melanogenesis occurs in melanophores and melanocytes differentiated from neural crest-derived melanoblasts.
- the aromatic amino acid tyrosine changes stepwise within the melanosome, and finally polymerizes non-enzymatically into melanin, followed by the formation of melanin granules.
- the component of the agent of the present invention not only has high melanin production inhibitory activity but is not cytotoxic.
- Such a preferable effect can be represented by a value obtained by multiplying the melanin production inhibition rate and the cell survival rate, as described in Examples described later.
- a person skilled in the art confirms and measures the presence and / or degree of the ability to suppress melanin production and the presence and / or degree of cytotoxicity using known means as appropriate, for example, using B16 melanoma cells. can do.
- known means for example, using B16 melanoma cells. can do.
- the presence and / or degree of melanin production inhibitory activity is based on the method described in the examples of the present specification, unless otherwise specified.
- “Maillard reaction” refers to a reaction in which a brown substance (melanoidin) is generated from a sugar and a protein by an aminocarbonyl reaction, unless otherwise specified.
- the Maillard reaction is usually a non-enzymatic reaction in which an Amadori rearrangement product (Amadori compound) is generated after a reducing sugar reacts with an amino group of a protein to form a Schiff base. Then, through complex reactions such as oxidation, dehydration, condensation, intramolecular and intermolecular cross-linking, the mixture gradually becomes yellowish brown and AGEs (advanced glycation end products) which are late stage products of the Maillard reaction are produced.
- Amadori rearrangement product Amadori compound
- the Maillard reaction that occurs in vivo is considered to be involved in the formation of brown spots on the skin seen in diabetic patients.
- AGE is included in the pigment that causes brown spots.
- In vivo Maillard reaction has also been shown to be associated with lifestyle-related diseases, diseases accelerated by aging (eg, diabetic complications, Alzheimer's disease, arteriosclerosis).
- AGE is a generic name for various structures produced from the Amadori rearrangement product through complex reactions such as oxidation, dehydration, and condensation, including carboxymethyllysine, pyralin, pentosidine, croslin, imidazolone, etc.
- a polymer of protein dimer or higher is also known as AGE.
- the term “antioxidation” means that the active oxygen is suppressed (not generated, erased, or suppressed) unless otherwise specified.
- a person skilled in the art can appropriately confirm and measure the presence and / or degree of the antioxidant ability of a subject using known means.
- DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging, superoxide dismutase (SOD) -like action, hydrogen peroxide (H 2 O 2 ) scavenging, TRAP (Total Radical-trapping Antioxidant Parameter), FRAP (Ferric Reducing Ability of Plasma), ⁇ -carotene fading, etc.
- SOD superoxide dismutase
- H 2 O 2 hydrogen peroxide
- TRAP Total Radical-trapping Antioxidant Parameter
- FRAP Frerric Reducing Ability of Plasma
- ⁇ -carotene fading etc.
- the presence or absence and / or degree of antioxidant ability refers to the methods described in the examples of the present specification (DPPH radical elimination method, SOD method, H 2 O 2 elimination method) unless otherwise specified. It depends on either.
- “suppressing the progress of aging” means delaying the progress of aging. Suppression of the progress of aging is sometimes expressed as anti-aging or anti-aging.
- the extract of ume that can be used in the composition of the present invention refers to a product obtained by extracting each part of the ume with a solvent (including liquid and gaseous states). You may use each part of a ume after freeze-drying.
- the solvent to be extracted include water (including a liquid obtained by subjecting a specific portion of ume to steam distillation), steam, purified water, mineral water, lower alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.), polyhydric alcohols (glycerin, propylene glycol, 1,3-butylene glycol, etc.), ketones (acetone, methyl ketone, etc.), ethers (diethyl ether, tetrahydrofuran, etc.) ).
- polar solvents such as steam, purified water, steam distilled liquid, mineral spring water, lower alcohols, polyhydric alcohols, particularly preferably purified water, steam distilled liquid, mineral water, ethanol, propylene glycol, 1,3 -Butylene glycol is good. These solvents may be used alone or in combination of two or more.
- the composition of the present invention may also contain an extract obtained from each of a plurality of extraction solvents.
- the composition of the present invention contains an ethanol extract (an extract using 90% or more of ethanol), according to the study by the present inventors, the ume ethanol extract contains a hardly water-soluble component. Therefore, in order to solubilize in the composition and enhance the stability, it is preferable to further include an emulsifier as described later.
- an ethanol extract an extract using ethanol having a purity of 90% or more
- water including a liquid obtained by subjecting a specific part of ume to steam distillation
- the purity of the solvent and the concentration of the mixed solvent for example, 95% ethanol
- it is based on the volume unless otherwise specified.
- a steam distilled liquid is used as an extraction solvent and is added to the composition as it is.
- the steam distilled liquid is obtained by continuously applying heated steam to a target (for example, ume fruit or ume shoots) in a container and cooling and collecting the steam flowing out from the container.
- the obtained liquid may contain various components derived from the subject.
- composition of the present invention is composed of two or more components, preferably in a form suitable for external use on the skin or as a food, and more preferably in the form of a cosmetic or health food.
- the composition or agent of the present invention does not include existing cosmetics and the like. Regarding the present invention, the description of the composition also applies to the agent unless otherwise specified.
- the content of the ume extract is not particularly limited as long as the intended effect is exhibited.
- concentration of the ume extract in an agent by this invention it is the value calculated based on the weight of the ume extract with respect to the composition total weight except the case where it describes especially.
- the weight of the ume extract was soaked in a solvent so that the dried ume portion was 5% W / W, and was kept at 20 to 40 ° C. for 3 to 5 days (medium 2 to 4). It is the weight expressed as the filtrate or dried product of the extract obtained by extraction between the two days. That is, the extract or dry matter obtained under other conditions is converted into the equivalent amount under the above conditions.
- composition of the present invention includes fats, waxes, hydrocarbons, fatty acids, alcohols, esters, amino acids, vitamins, which are components used in ordinary external preparations, as long as the desired effects are not impaired.
- Surfactants, pH adjusters, antiseptics, fragrances, moisturizers, powders, UV absorbers, thickeners, pigments, antioxidants, whitening agents, anti-inflammatory agents, anti-wrinkle agents, rough skin improvers, Components such as acne agents, alkalis, chelating agents, sequestering agents and the like can also be blended.
- ingredients such as sodium sulfate, sodium hydrogen carbonate, calcium carbonate, potassium chloride, oily ingredients, emulsifiers, succinic acid, herbal medicines, inorganic pigments, fragrances, and pigments, which are components used in ordinary bath additives, You can also.
- composition of the present invention can also be prepared into various dosage forms such as a solid agent, a semi-solid agent, and a liquid agent depending on the purpose of use.
- the composition of the present invention can be in any form of cosmetics, quasi drugs, and pharmaceuticals.
- cosmetics as skin care cosmetics, facial soap, facial cream, facial cleansing foam, lotion (replenishes the skin with moisture and moisturizing ingredients and keeps the skin fresh and is usually a transparent or translucent liquid. Depending on the intended use.
- an amount corresponding to the steam extract obtained by the method described in Example 1 of the present invention preferably, a steam distilled liquid of ume shoots.
- 10 to 50 g / 100 g, preferably 15 to 45 g / 100 g, more preferably 20 to 40 g / 100 g, and a steam distilled liquid obtained by the method described in Example 1 of the present invention preferably , A steam distilled liquid of ume fruit
- a steam distilled liquid of ume fruit can be blended in an amount of 35 to 65 g / 100 g, preferably 40 to 60 g / 100 g, more preferably 45 to 55 g / 100 g.
- 0.05 to 250 mg / 100 g, preferably 0.1 to 15 mg / 100 g, More preferably, 1-10 mg / 100 g can be blended, and the method described in Example 1 of the present invention
- 0.05 to 15 g / 100 g, preferably 0.1 to 10 g / 100 g, more preferably 0.5 to 5 g / 100 g may be blended. It can. Also in this case, each may be blended alone in the above amounts, or may be blended in combination in the above amounts. It is more preferable to combine them.
- blending amount of the ume extract in the present invention means an amount corresponding to the extract obtained by the method described in Example 1 of the present specification, unless otherwise specified.
- the ume extract is extracted with the ume extract obtained by the method described in Example 1 of the present invention (preferably, extraction of ume root with a ume shoot branch steam distillate).
- the amount corresponding to dry powder of ume extract (preferably, dry powder of extract of ume root with 95% ethanol) is 0.1 to 250 mg / 100 g, preferably 0.3 to 15 mg / 100 g, more preferably 0.5 to 10 mg. / 100g can be blended.
- the ume extract and the dried product may be blended alone in the above amounts or in combination. It is more preferable to combine them.
- the ume extract corresponds to the ume extract obtained by the method described in Example 1 of the present invention (preferably, the extract of the ume root by the ume shoot water vapor distillation solution). 0.01 to 30 g / 100 g, preferably 0.05 to 20 g / 100 g, more preferably 0.1 to 10 g / 100 g, and the amount of ume extract obtained by the method described in Example 1 of the present invention.
- the amount corresponding to the ume steam distillate (preferably ume fruit steam distillate) obtained by the method described in Example 1 of the present invention is 5 to 70 g / 100 g, preferably 10 to 60 g / 100 g, more preferably 20 to 50 g / 100 g can be blended.
- each extract may be blended alone in the above amount, or may be blended in combination in the above amount. It is more preferable to combine them.
- the ume extract is used as an amount corresponding to the ume steam distillate (preferably the ume fruit steam distillate) obtained by the method described in Example 1 of the present invention. 20 to 80 g / 100 g, preferably 30 to 70 g / 100 g, more preferably 40 to 60 g / 100 g.
- the ume extract corresponds to the ume extract obtained by the method described in Example 1 of the present invention (preferably, the extract of the ume root by the ume shoots steamed distillate). 0.1 to 20 g / 100 g, preferably 0.5 to 10 g / 100 g, more preferably 1 to 5 g / 100 g, and the dried ume extract obtained by the method described in Example 1 of the present invention.
- an amount corresponding to powder preferably dry powder of extract of ume root with 95% ethanol
- 0.01 to 250 mg / 100 g preferably 0.05 to 10 mg / 100 g, more preferably 0.2 to 5 mg / 100 g Can do.
- each extract may be blended alone in the above amount, or may be blended in combination in the above amount. It is more preferable to combine them.
- the composition of the present invention corresponds to a ume extract obtained by the method described in Example 1 of the present invention (preferably, an extract of ume roots using a ume sap branch steam distillation solution).
- the amount can be 0.05 to 10 g / 100 g, preferably 0.1 to 5 g / 100 g, more preferably 0.5 to 2 g / 100 g, and the dried ume extract obtained by the method described in Example 1 of the present invention.
- As an amount corresponding to powder preferably, dried powder of ume root extract with 95% ethanol
- 0.01 to 250 mg / 100 g, preferably 0.05 to 5 mg / 100 g, more preferably 0.3 to 1 mg / 100 g Can do.
- each extract may be blended alone in the above amount, or may be blended in combination in the above amount. It is more preferable to combine them.
- composition of the present invention is in the form of a lip base
- dried powder of ume extract obtained by the method described in Example 1 of the present invention preferably dried powder of ume root extract with 95% ethanol
- an extract preferably, an extract of ume roots with a ume shoot steamed distillate and / or a purified water extract of ume roots
- each extract may be blended alone in the above amount, or may be blended in combination in the above amount. It is more preferable to combine them.
- the ume extract is converted into a ume extract obtained by the method described in Example 1 of the present invention (preferably, an extract of ume roots using a ume sap branch steam distillation solution).
- a corresponding amount 0.01 to 30 g / 100 g, preferably 0.5 to 20 g / 100 g, more preferably 1 to 10 g / 100 g can be blended, and the ume extract obtained by the method described in Example 1 of the present invention.
- 0.01 to the dry powder preferably, dried powder of ume root extract with 95% ethanol
- 0.01 to 250 mg / 100 g preferably 0.05 to 10 mg / 100 g, more preferably 0.1 to 5 mg / 100 g can do.
- each extract may be blended alone in the above amount, or may be blended in combination in the above amount. It is more preferable to combine them.
- composition of the present invention is in the form of a cosmetic
- an effective amount of an emulsifier is included to solubilize the ume extract.
- emulsifiers are various effects of ume extract, namely elastase activity inhibition effect, gelatinase activity inhibition effect, collagenase activity inhibition effect, hyaluronidase activity inhibition effect, fibroblast activation (activity, effect), melanin production inhibition effect, Maillard
- the reaction suppressing effect and the antioxidant effect can be synergistically enhanced.
- emulsifiers that can be used in the present invention are lecithin, lecithin derivatives, lysophospholipid, polymer emulsifier, propylene glycol fatty acid ester, glycerin fatty acid ester, polyglycerin fatty acid ester, polyoxyethylene glycerin fatty acid ester, sorbitan fatty acid ester, poly Oxyethylene sorbitan fatty acid ester, polyoxyethylene sorbit fatty acid ester, polyoxyethylene lanolin, lanolin alcohol, beeswax derivative, polyoxyethylene hydrogenated castor oil, polyoxyethylene sterol, hydrogenated sterol, polyoxyethylene alkyl ether, polyoxyethylene poly Oxypropylene alkyl ether, polyoxyethylene alkyl ether phosphate / phosphate, polyethylene glycol fatty acid ester It is an ether.
- lecithin and lecithin derivatives include fractionated lecithin, enzymatically degraded lecithin (including lysolecithin), and hydrogenated lecithin (sometimes referred to as “hydrogenated lecithin”). More specific preferable examples of the emulsifier that can be used in the present invention are expressed as lysolecithin, hydrogenated lecithin, hydrogenated lysolecithin (lysophospholipid, hydrogenated phospholipid, hydrogenated lysophospholipid) derived from soybean or egg yolk. There is also.). Lecithin and lecithin derivatives can also be used in combination.
- emulsifiers include lysolecithin, PEG-60 hydrogenated castor oil, hydrogenated lecithin, soybean sterol, or any combination thereof in an amount effective to solubilize the ume extract in the composition of the present invention.
- the blending amount is 0.015 g / 100 g or more, preferably 0.025 g / 100 g, more preferably 0.05 g / 100 g. In any case, it is preferably 5 g / 100 g or less, more preferably 2.5 g / 100 g or less.
- the upper limit value may be determined in consideration of viscosity.
- the composition of the present invention may contain 0.001 to 10 g / 100 g, preferably 0.002 to 5 g / 100 g, more preferably 0.002 to 3 g / 100 g.
- composition of the present invention is in the form of a cosmetic, in a particularly preferred embodiment, it is used immediately after washing the face.
- various effects of ume extract namely elastase activity inhibitory effect, gelatinase activity inhibitory effect, collagenase activity inhibitory effect, hyaluronidase activity inhibitory effect, fibroblast activation (activity, effect), melanin production inhibitory effect, Maillard reaction inhibitory effect and antioxidant effect can be synergistically enhanced.
- composition of the present invention is in the form of a cosmetic
- its production method is not particularly limited as long as the effect of the ume extract is not significantly reduced, and can be appropriately produced by those skilled in the art.
- the production process includes a high-pressure emulsification treatment process.
- the emulsified particles can be made fine and an emulsified state with high stability can be created.
- a ume extract that is relatively difficult to disperse can be sufficiently dispersed and stabilized, facilitating blending.
- the emulsified particles become finer, have better skin fit, increase permeability, and various effects of ume extract: elastase activity inhibitory effect, gelatinase activity inhibitory effect, collagenase activity inhibitory effect, hyaluronidase activity inhibitory effect, fiber
- elastase activity inhibitory effect gelatinase activity inhibitory effect
- collagenase activity inhibitory effect hyaluronidase activity inhibitory effect
- fiber A cosmetic product that synergistically enhances blast cell activation (activity, effect), melanin production inhibitory effect, Maillard reaction inhibitory effect, and antioxidant effect can be produced.
- the production process includes a deodorization process separately from or in combination with the high-pressure emulsification treatment process.
- extracts from various parts of ume may have a characteristic odor derived from the raw material, and when a cosmetic composition is constituted, even in a relatively small amount, It may not be negligible to apply to the face. This tendency was particularly remarkable when roots were used.
- the means for deodorization is not particularly limited as long as the effect of the ume extract is not significantly reduced, and an existing technique used for the same purpose can be applied.
- One typical method is to use activated carbon.
- the ume extract is obtained from the ume extract obtained by the method described in Example 1 of the present invention (preferably, an extract of ume root using a ume shoot with a steamed ume branch).
- an amount corresponding to the above 0.01 to 30 g / 100 g, preferably 0.5 to 20 g / 100 g, more preferably 1 to 10 g / 100 g can be blended, and the ume extract obtained by the method described in Example 1 of the present invention
- the amount corresponding to the dry powder of the product preferably, the dried powder of the extract of ume root with 95% ethanol
- each extract may be blended alone in the above amount, or may be blended in combination in the above amount. It is more preferable to combine them.
- Example 1 Preparation of ume part extract
- the ume part extract obtained as needed was powdered.
- the extract with purified water was freeze-dried and powdered. After removing the solvent from the ethanol extract once using an evaporator, an appropriate amount of purified water was added, freeze-dried, and powdered.
- the steam distilled liquid of a ume fruit or a young branch was prepared as follows.
- Ume fruit steam distillate Water vapor generated by boiling purified water was applied to 5 to 50% (w / w) of ume fruits, and the water vapor containing aroma components obtained was cooled.
- Ume Wakae Steam Distillate Water vapor generated by boiling purified water was applied to 0.01 to 10% (w / w) of ume shoots to cool the water vapor containing aroma components obtained.
- Test method 50 ⁇ L of an evaluation sample prepared using purified water on a 96 well plate, 35 ⁇ L of 0.1 M Tris-HCl buffer, 100 ⁇ L of 1 mM Suc-Ala-Ala-Ala-PNA, 0.25 U / mL (Wako Pure Chemical Industries, Ltd., 15 ⁇ L (derived from porcine pancreas) was added, and after reacting at 37 ° C. for 30 minutes, absorbance at 405 nm was measured with a microplate reader. The inhibition rate was calculated using the following formula with purified water as a control.
- Test sample 25 (L, 2 mM hypoxanthine 25 (L, 2 mM EDTA 25 (L, 0.5 mM NBT 25 (L, 0.1 M carbonate buffer 100 (L , 30 mU / mL xanthine oxidase (XOD) 50 (L was added, reacted at 37 ° C. for 30 minutes, and the absorbance at 570 nm was measured with a microplate reader. The elimination rate was calculated using the following formula with purified water as a control. .
- Hydrogen peroxide (H 2 O 2 ) erasing effect test 25 ⁇ L of an evaluation sample prepared with purified water was added to a 96-well plate, and then 10 ⁇ L of 0.15 mM H 2 O 2 and 25 ⁇ l of 0.1 M PIPES buffer (pH 7.0) were added and reacted at 37 ° C. for 20 minutes. . Immediately after the reaction, 172 ⁇ M DA-67 (180 ⁇ L) was added, ethanol (10 ⁇ L) was added, a color reaction was performed at 37 ° C. for 5 minutes, and the absorbance at 630 nm was measured with a microplate reader. The elimination rate was calculated using the following formula with purified water as a control.
- Hyaluronidase activity inhibitory effect test Evaluation sample prepared using purified water in a 96-well plate 12 ⁇ L, 400U / mL hyaluronidase (SIGMA, cow testis) 12 ⁇ L was mixed and incubated at 40 ° C for 20 minutes, 0.1mg / mL Compound 48/80 12 ⁇ L And react at 40 ° C for 20 minutes, add 12 mg of 1 mg / mL potassium hyaluronate, and react at 40 ° C for 40 minutes.
- the hyaluronidase activity inhibitory effect is calculated using the following formula.
- Collagenase activity inhibitory effect test 60 ⁇ L of an evaluation sample prepared using purified water, 480 ⁇ L of 0.5 M pz-peptide adjusted with 0.1 M Tris-HCl buffer (pH 7.1, containing 20 mM CaCl 2 ), and 50 CDU / mL collagenase adjusted with purified water ( 60 ⁇ L (from SIGMA, Clostridium histolyticum ) was added and reacted at 37 ° C. for 30 minutes. Immediately after the reaction, 1.2 mL of 2.5 mM citric acid was added, and then extracted with 5.0 mL of ethyl acetate. After centrifugation, the absorbance at 320 nm of the ethyl acetate layer was measured. Using purified water as a control, the inhibition rate of collagenase activity was calculated using the following formula.
- Fibroblast activation effect test Normal human dermal fibroblasts (NHDF) were seeded in a 96-well microplate at a density of 7 ⁇ 10 4 cells / cm 2 .
- NHDF normal human dermal fibroblasts
- an ⁇ -MEM medium containing 5% fetal bovine serum (FBS) was used and cultured in a CO 2 incubator (5% CO 2 , 37 ° C.) for 24 hours. After 24 hours, each sample was replaced with ⁇ -MEM medium containing 5% FBS, and cultured for 72 hours.
- FBS fetal bovine serum
- MTT 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide
- DMEM medium supplemented with 1.0 mg / ml and cultured for 4 hours.
- the produced formazan was extracted with acidic isopropanol, and the absorbance at wavelengths of 570 nm and 630 nm was measured with a plate reader. From the difference between the two measured values (absorbance at 570 nm ⁇ absorbance at 630 nm), the cell activation effect was evaluated using the following formula with the value in the case of addition of purified water as a control as the activation rate of 100%.
- B16 melanoma cell melanin production inhibitory effect test Prepare B16 melanoma cells in DMEM medium containing 10% fetal bovine serum (FBS) at 12 ⁇ 10 4 cells / mL, seed the cell suspension at 0.5 mL / well in a 24-well plate (2 cm 2 ), 37 ° C, Incubate under 5% CO 2 . After 24 hours, the medium is replaced with 0.1 mg / mL theophylline and DMEM medium (10% FBS) supplemented with the evaluation sample.
- FBS fetal bovine serum
- Gelatinase activity inhibitory effect test A 10% SDS polyacrylamide gel containing 0.2% gelatin is prepared without a comb by adding a pre-heated gelatin solution, and the MMP marker (manufactured by Primary Cell Co., Ltd.) is 1/4 and 1.5M Tris-HCl buffer (pH 8.8). Apply the sample diluted in step) and perform electrophoresis. After electrophoresis, wash repeatedly with 2.5% TritonX-100. Cut into strips with a length of 2 cm and a width of 0.4 cm from a position 5 mm below the boundary between the separation gel and the concentrated gel.
- Hyaluronidase activity inhibitory effect The lyophilized product obtained by the method of Example 1 was redissolved in each solvent and used for the test. A similar test was conducted for sodium cromoglycate. The test results are shown in the table below.
- Example 3 activated carbon treatment
- Example 2 the elastase activity inhibitory effect test was carried out by the method described in Example 2 for the product after the activated carbon treatment, and compared with the result for the product before the treatment.
- EtOH extraction refers to extraction with 95% ethanol (the same applies to the following examples unless otherwise noted).
- the odor derived from the material was reduced, and the activity was not significantly reduced, making it more suitable as a raw material to be added to cosmetics.
- the aqueous phase A having the composition shown in the following table was heated and dissolved at 85 ° C., B was added, and the mixture was stirred.
- the oil phase C was heated and dissolved at 100 ° C.
- the oil phase C was added to the aqueous phase A and B mixture, heated to 85 ° C., and emulsified with an emulsifier. Thereafter, it was cooled to 35 ° C. and subjected to high-pressure treatment (220 MPa ⁇ 5 pass) to obtain a pre-treatment liquid for serum.
- aqueous phase A shown in the table below was heated and dissolved at 85 ° C. and cooled to 37 ° C.
- Each component of B was added to aqueous phase A, and C (the essence pretreatment product obtained in the above step (a)) was added to the mixture of aqueous phases A and B, and dispersed uniformly to obtain a essence. .
- aqueous phase A having the composition shown in the table below was dissolved by heating to 75 ° C., cooled to 35 ° C., added with aqueous phase B, and stirred. Finally, C was added in small portions and stirred to obtain a comparative cosmetic liquid.
- the sensory test of the manufactured cosmetics was conducted by 20 panelists (general women in their 20s and 60s).
- the cosmetic liquids of the examples were superior in all items as compared to the comparative examples.
- Example 5 Preparation of cosmetics, etc.
- Manufacture of lotion 1 In the following table, heat to 75 ° C and dissolve with stirring. After cooling to 35 ° C., a lotion was obtained.
- aqueous phase A having the composition shown in the table below is heated to 85 ° C. and dissolved.
- Add B the pre-treatment for the lotion / milky emulsion obtained in step (a) of lotion 2 and stir. Heat and dissolve only C. C is added to the mixture of A and B, heated to 85 ° C. and emulsified with an emulsifier. The emulsion was cooled to 35 ° C. to obtain an emulsion.
- Oil phase A having the composition shown in the following table is heated to 100 ° C. and dissolved.
- Test on blending amount of emulsifier [Test 1] Test method: Add ume extract (dry powder of 95% ethanol extract of Shirakaga ume root) to purified water at a concentration of 0.1 mg / mL (approximately the same as 0.1 mg / g), and add emulsifier (PEG-60 hydrogenated castor oil). The test samples were mixed at the concentrations shown in the table below. In addition, the sample was heated at 80 ° C. to 95 ° C., then mixed by vortexing for 1 minute or longer, and photographed to confirm the presence or absence of precipitation.
- ume extract dry powder of 95% ethanol extract of Shirakaga ume root
- emulsifier PEG-60 hydrogenated castor oil
- Test method A ume extract (dry powder of Shirakaga ume root 95% ethanol extract) was dissolved in purified water at a concentration of 0.25 wt%, and an emulsifier was mixed at the following concentration to prepare a test sample.
- an emulsifier four kinds of lysolecithin, PEG-60 hydrogenated castor oil, hydrogenated lecithin, and soybean sterol were blended at the same ratio as in Example [Table 9] of the present specification.
- the sample was heated at 80 ° C. to 95 ° C., then mixed by vortexing for 1 minute or more and cooled to room temperature. The cooled sample was centrifuged at 500 rpm for 2 minutes and photographed to confirm the presence or absence of precipitation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
La présente invention concerne une composition destinée à être appliquée de manière externe sur la peau et contenant une quantité efficace d'un extrait d'au moins une partie de prunier (Prunus mume) choisie parmi la racine, les branches et l'écorce et un solvant aqueux. Ladite composition est particulièrement utile pour inhiber l'activité d'une élastase et/ou d'une hyaluronidase. L'extrait de prunier peut être utilisé à des fins anti-vieillissement et/ou de blanchiment de la peau.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-094031 | 2010-04-15 | ||
JP2010094031A JP4795475B1 (ja) | 2010-04-15 | 2010-04-15 | ウメ抽出物を含む剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011129428A1 true WO2011129428A1 (fr) | 2011-10-20 |
Family
ID=44798796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/059358 WO2011129428A1 (fr) | 2010-04-15 | 2011-04-15 | Composition cosmétique contenant de l'extrait de prunier |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4795475B1 (fr) |
WO (1) | WO2011129428A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013144654A (ja) * | 2012-01-13 | 2013-07-25 | Koshiro Co Ltd | ウメの花部抽出物を含むコラーゲン収縮力低下抑制用組成物 |
CN104173220A (zh) * | 2013-05-23 | 2014-12-03 | 伽蓝(集团)股份有限公司 | 绿萼梅提取物用作抗羰基化反应有效成分的新用途 |
CN104173221A (zh) * | 2013-05-23 | 2014-12-03 | 伽蓝(集团)股份有限公司 | 绿萼梅提取物的新用途 |
CN109303723A (zh) * | 2017-07-27 | 2019-02-05 | 伽蓝(集团)股份有限公司 | 梅花花胚提取物及其制备方法和应用 |
JP2022134637A (ja) * | 2021-03-03 | 2022-09-15 | みなべ町 | コラゲナーゼ阻害剤 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5981716B2 (ja) * | 2011-03-25 | 2016-08-31 | 株式会社コーセー | 梅酢含有化粧料、及び梅酢を有効成分とする薬効剤 |
CN107072936A (zh) * | 2015-08-10 | 2017-08-18 | 玫琳凯有限公司 | 局部用组合物 |
CN107019207B (zh) * | 2016-02-02 | 2022-03-18 | 林岳辉 | 植物自体萃取营养份的方法及营养份 |
KR102040245B1 (ko) * | 2017-04-24 | 2019-11-07 | 주식회사 코씨드바이오팜 | 알로에베라잎에 초정 광천수를 첨가하여 추출한 추출물을 함유하는 피부보습용 또는 피부노화방지용 화장료 조성물 |
WO2019111415A1 (fr) | 2017-12-08 | 2019-06-13 | ワミレスコスメティックス株式会社 | Vésicule cationisée, et composition associée |
CN114569512A (zh) * | 2022-03-22 | 2022-06-03 | 厦门碱起来食品有限公司 | 一种青梅提取物及其制备方法和应用 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11335235A (ja) * | 1998-05-22 | 1999-12-07 | Shiseido Co Ltd | 抗老化剤 |
JP2000191513A (ja) * | 1998-12-25 | 2000-07-11 | Michio Yoshida | アガリクス茸抽出液を含有する皮膚洗浄料 |
JP2001316221A (ja) * | 2000-05-10 | 2001-11-13 | Naris Cosmetics Co Ltd | 抗老化剤および化粧料 |
JP2002201121A (ja) * | 2000-12-28 | 2002-07-16 | Azuma Noen:Kk | 化粧品用梅水 |
JP2002241293A (ja) * | 2001-02-13 | 2002-08-28 | Ichimaru Pharcos Co Ltd | メイラード反応阻害剤 |
JP2002284648A (ja) * | 2001-03-27 | 2002-10-03 | National Institute Of Advanced Industrial & Technology | 育毛剤組成物 |
JP2002284633A (ja) * | 2001-03-28 | 2002-10-03 | Katakura Chikkarin Co Ltd | 化粧料 |
JP2002370922A (ja) * | 2001-06-15 | 2002-12-24 | Azuma Noen:Kk | 梅抽出物を含む化粧品 |
JP2006096716A (ja) * | 2004-09-30 | 2006-04-13 | Mitsui Chemicals Inc | 使用感改善剤 |
JP2007038115A (ja) * | 2005-08-02 | 2007-02-15 | Dainippon Kasei Kk | 生物由来成分抽出法 |
JP2009263275A (ja) * | 2008-04-25 | 2009-11-12 | Kracie Home Products Ltd | 抗酸化剤並びにそれを含有する化粧料、飲食品組成物及び医薬品組成物 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4205188B2 (ja) * | 1997-10-01 | 2009-01-07 | 一丸ファルコス株式会社 | メイラード反応阻害剤 |
JP2001139421A (ja) * | 1999-11-18 | 2001-05-22 | Takashi Miyazaki | 経皮・経口混合粉末 |
JP2001302439A (ja) * | 2000-04-25 | 2001-10-31 | Matsukawa Kagaku:Kk | 白桃花から抽出した抽出物を含有する化粧料 |
JP2002080338A (ja) * | 2000-06-20 | 2002-03-19 | Shiseido Co Ltd | 老化防止用皮膚外用剤 |
JP2002020225A (ja) * | 2000-07-10 | 2002-01-23 | Naris Cosmetics Co Ltd | 保湿組成物 |
JP2004182687A (ja) * | 2002-12-05 | 2004-07-02 | Kao Corp | エラスターゼ阻害剤 |
JP2005126360A (ja) * | 2003-10-23 | 2005-05-19 | Masao Tanihara | 新規なポリペプチドで構成されたコラゲナーゼ阻害剤 |
JP2006008566A (ja) * | 2004-06-24 | 2006-01-12 | Ichimaru Pharcos Co Ltd | 果汁の乳酸菌醗酵物を有効成分とする美容剤とその応用 |
JP4707997B2 (ja) * | 2004-07-30 | 2011-06-22 | 昭和電工株式会社 | L−アスコルビン酸−2−リン酸エステルマグネシウムナトリウム塩、その製造方法および該塩を含有する化粧料 |
JP4634769B2 (ja) * | 2004-10-04 | 2011-02-16 | 独立行政法人産業技術総合研究所 | 美白効果向上剤、その製造方法、それを用いた美白剤組成物及びそれを含有する皮膚外用剤 |
JP2006176425A (ja) * | 2004-12-21 | 2006-07-06 | Maruzen Pharmaceut Co Ltd | コラーゲン産生促進剤及び皮膚外用剤 |
WO2008093670A1 (fr) * | 2007-02-01 | 2008-08-07 | Tk Bio-Research Laboratory Co., Ltd. | Produit de fermentation à base de pellicule/pépin de raisin obtenu à l'aide de bactéries lactiques et agent pharmaceutique et aliment l'utilisant |
JP5057808B2 (ja) * | 2007-03-14 | 2012-10-24 | ポーラ化成工業株式会社 | 保湿性に優れる皮膚外用剤 |
JP2008266147A (ja) * | 2007-04-16 | 2008-11-06 | Sapporo Breweries Ltd | 細胞外マトリックス分解酵素阻害剤 |
JP5162174B2 (ja) * | 2007-07-24 | 2013-03-13 | 丸善製薬株式会社 | 育毛剤及び抗肥満剤 |
JP2009051803A (ja) * | 2007-08-28 | 2009-03-12 | Yoshiaki Nagaura | 新しい抽出方法の発見 |
JP2009107983A (ja) * | 2007-10-31 | 2009-05-21 | Maruzen Pharmaceut Co Ltd | メイラード反応阻害剤並びに抗老化剤及び皮膚外用剤 |
JP2009263279A (ja) * | 2008-04-25 | 2009-11-12 | Oriza Yuka Kk | エラスターゼ阻害剤 |
JP2010047530A (ja) * | 2008-08-22 | 2010-03-04 | Intoron:Kk | 植物抽出物を含有する化粧料 |
-
2010
- 2010-04-15 JP JP2010094031A patent/JP4795475B1/ja active Active
-
2011
- 2011-04-15 WO PCT/JP2011/059358 patent/WO2011129428A1/fr active Application Filing
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11335235A (ja) * | 1998-05-22 | 1999-12-07 | Shiseido Co Ltd | 抗老化剤 |
JP2000191513A (ja) * | 1998-12-25 | 2000-07-11 | Michio Yoshida | アガリクス茸抽出液を含有する皮膚洗浄料 |
JP2001316221A (ja) * | 2000-05-10 | 2001-11-13 | Naris Cosmetics Co Ltd | 抗老化剤および化粧料 |
JP2002201121A (ja) * | 2000-12-28 | 2002-07-16 | Azuma Noen:Kk | 化粧品用梅水 |
JP2002241293A (ja) * | 2001-02-13 | 2002-08-28 | Ichimaru Pharcos Co Ltd | メイラード反応阻害剤 |
JP2002284648A (ja) * | 2001-03-27 | 2002-10-03 | National Institute Of Advanced Industrial & Technology | 育毛剤組成物 |
JP2002284633A (ja) * | 2001-03-28 | 2002-10-03 | Katakura Chikkarin Co Ltd | 化粧料 |
JP2002370922A (ja) * | 2001-06-15 | 2002-12-24 | Azuma Noen:Kk | 梅抽出物を含む化粧品 |
JP2006096716A (ja) * | 2004-09-30 | 2006-04-13 | Mitsui Chemicals Inc | 使用感改善剤 |
JP2007038115A (ja) * | 2005-08-02 | 2007-02-15 | Dainippon Kasei Kk | 生物由来成分抽出法 |
JP2009263275A (ja) * | 2008-04-25 | 2009-11-12 | Kracie Home Products Ltd | 抗酸化剤並びにそれを含有する化粧料、飲食品組成物及び医薬品組成物 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013144654A (ja) * | 2012-01-13 | 2013-07-25 | Koshiro Co Ltd | ウメの花部抽出物を含むコラーゲン収縮力低下抑制用組成物 |
CN104173220A (zh) * | 2013-05-23 | 2014-12-03 | 伽蓝(集团)股份有限公司 | 绿萼梅提取物用作抗羰基化反应有效成分的新用途 |
CN104173221A (zh) * | 2013-05-23 | 2014-12-03 | 伽蓝(集团)股份有限公司 | 绿萼梅提取物的新用途 |
CN109303723A (zh) * | 2017-07-27 | 2019-02-05 | 伽蓝(集团)股份有限公司 | 梅花花胚提取物及其制备方法和应用 |
JP2022134637A (ja) * | 2021-03-03 | 2022-09-15 | みなべ町 | コラゲナーゼ阻害剤 |
JP7235233B2 (ja) | 2021-03-03 | 2023-03-08 | みなべ町 | コラゲナーゼ阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
JP2013163643A (ja) | 2013-08-22 |
JP4795475B1 (ja) | 2011-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4795475B1 (ja) | ウメ抽出物を含む剤 | |
RU2545708C2 (ru) | Экстракт цельных семян moringa sp. и его применение в косметических и/или дерматологических композициях | |
JP7357983B2 (ja) | モリンガ・ペレグリナ種子固形物の抽出物、それを得るための方法、及び美容用品組成物若しくはニュートリコスメティクス組成物におけるその使用 | |
KR101744889B1 (ko) | 항산화, 미백 및 주름개선 효과를 갖는 조성물 | |
KR102561149B1 (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
KR101095609B1 (ko) | 미백 복합물을 함유하는 피부미백용 화장료 조성물 | |
KR101445642B1 (ko) | 배롱나무 추출물을 유효성분으로 함유하는 화장료 조성물 | |
US10980736B2 (en) | Coconut shell extracts, compositions containing same and uses | |
JP2012162487A (ja) | 美白剤、抗老化剤及び皮膚化粧料 | |
KR102573375B1 (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
KR101176526B1 (ko) | 조팝나무 추출물을 유효성분으로 함유하는 화장료 조성물 | |
KR20170137405A (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
KR20170137436A (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
KR20170137559A (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
KR102503191B1 (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
KR102573376B1 (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
KR102561150B1 (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
KR101479245B1 (ko) | 배롱나무 추출물을 유효성분으로 함유하는 화장료 조성물 | |
KR101479244B1 (ko) | 배롱나무 추출물을 유효성분으로 함유하는 화장료 조성물 | |
KR102561151B1 (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
KR100516447B1 (ko) | 수렴효과가 우수한 갈근추출물 함유 화장료 조성물 | |
KR102561146B1 (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
KR20170136922A (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
KR102573377B1 (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
KR20170137557A (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11768949 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11768949 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |